Partnership expands to develop a new treatment for pachyonychia congenita

19 Feb 2019

MedPharm and Palvella Therapeutics hope to develop the first approved treatment for PC in the US and Europe.

MedPharm has announced the expansion of their partnership with Palvella Therapeutics. To date, MedPharm has employed its specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase II/III clinical study.

Partnership expands to develop a new treatment for pachyonychia congenita

“MedPharm is very proud to be part of a collaboration with Palvella and the PC community which will potentially benefit PC patients directly. Currently this is a serious unmet medical need that has no approved treatments,” said Professor Marc Brown, MedPharm’s CSO and co-founder. “I have met many PC patients over the years and am excited to be continuing our support of Palvella and PC Project as they move closer to making a real difference to these patients’ lives.”

“We are very pleased with the expertise and the results that MedPharm have brought to Palvella’s lead development program for PC,” added Wes Kaupinen, Palvella’s President and CEO. “In addition to their rigorous scientific approach, the actions of the entire MedPharm organization, from their dedicated scientists to their senior leadership, have shown a deep commitment to working towards the betterment of patients suffering from PC.”

PC is a rare, chronically debilitating, and lifelong genetic disease in which mutated genes responsible for keratin production lead to extreme cell fragility. This dramatically limits patients’ ability to walk and perform everyday tasks. Most patients suffer from deformed nails and almost all experience some level of pain. No treatments are currently approved for PC in the US or Europe.

As it has advanced the PTX-022 project, MedPharm has remained attentive to the needs of PC patients as part of the company’s partnership with Palvella, and has attended Pachyonychia Congenita Project (PC Project) patient meetings where research is discussed and patient feedback is collected.

Read More

Related news

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Envigo launches PATHWAY to enable FIH clinical trials

Envigo launches PATHWAY to enable FIH clinical trials

11 Mar 2019

PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more 
Uniqsis expands LED photoreactor range

Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Read more 
Crowdfund and discover promising therapeutics via Molecule

Crowdfund and discover promising therapeutics via Molecule

21 Feb 2019

Connecting scientists, patients, and industry to advance drug development in a collaborative open market.

Read more 
Chemspace and LabNetwork collaborate to extend access to chemical databases

Chemspace and LabNetwork collaborate to extend access to chemical databases

14 Feb 2019

Collaboration provides drug discovery researchers access to European distribution and local support for library of in-stock and on-demand compounds.

Read more 
SGS to conduct its first malaria human challenge trial in Belgium

SGS to conduct its first malaria human challenge trial in Belgium

13 Feb 2019

The advanced candidate compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria.

Read more 
New API screening program strengthens Particle Sciences' nanomilling offering

New API screening program strengthens Particle Sciences' nanomilling offering

22 Jan 2019

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

Read more 
Preparing samples of cannabis plant for THC/CBD analysis

Preparing samples of cannabis plant for THC/CBD analysis

15 Jan 2019

Porvair Sciences has created a solid, stable and strong microplate that can withstand the applied forces in bead-beaters while maintaining a standard ANSI/SLAS footprint and key dimensions.

Read more 
Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more